文献速递肾移植

已故供者获取活检实践、判读及基于组织学的决策:美国肾移植中心调查

Deceased Donor Procurement Biopsy Practices, Interpretation, and Histology-Based Decision-Making: A Survey of US Kidney Transplant Centers.
PubMed 文献 · Kidney Int Rep · 2022-03-28

该调查于2021年4月22日至6月30日以电子问卷评估美国95个肾移植中心(占全美40%、近期已故供肾移植量50%)的供者活检指征、频率、处理与判读及其对器官接受决策的影响。结果显示35%中心对多数至全部肾脏行获取活检,57%使用半定量评分,37%很少或从无肾脏专科病理医师可及,72%表示有利活检结果会鼓励接受边缘供肾。结论认为获取活检虽常用,但病理可及性与判读标准不一致,需进一步研究与共识建设。

要点

  • 35%的移植中心对多数至全部肾脏行获取活检。
  • 57%受访者使用半定量评分系统判读活检。
  • 72%表示有利活检结果会鼓励接受边缘供肾。

核心结论

  • 获取活检在器官接受决策中常用,但肾脏专科病理医师可及性不一致,指征、评分与判读方法异质。
  • 需要持续研究与共识建设,以引导获取活检实践提高器官利用并减少分配低效。

研究设计与样本

  • 于2021年4月22日至2021年6月30日向美国肾移植项目临床人员发放电子调查问卷。
  • 分析95个移植中心参与器官接受人员的回复(73%外科医师、20%肾内科医师、6%协调员),占美国移植中心40%及近期已故供肾移植量50%。

主要发现

  • 35%的中心报告对多数至全部肾脏行获取活检。
  • 82%的临床医师与器官获取组织(OPO)共同决定何时活检,72%基于正式标准决策,但41%报告曾在标准之外请求活检。
  • 57%的受访者使用半定量评分系统判读,37%很少或从无肾脏专科病理医师可及,59%很少或从无远程病理可及。
  • 72%的受访者报告有利活检结果会鼓励接受「边缘」供肾,46%表示不利活检结果会导致拒绝标准标准供肾。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The utility of kidney procurement biopsies is controversial. Understanding the current landscape of how clinicians obtain and use biopsies in organ evaluation may help inform consensus-building efforts. METHODS: An electronic survey was distributed to clinicians at US kidney transplant programs (April 22, 2021-June 30, 2021) to evaluate donor biopsy indications, frequency, processing and interpretation, and impact of findings on practices. RESULTS: Responses from staff involved in organ acceptance (73% surgeons, 20% nephrologists, 6% coordinators) at 95 transplant centers were analyzed, representing 40% of US transplant centers and 50% of recent deceased donor kidney transplant volume. More than a third of centers (35%) reported obtaining procurement biopsies on most-to-all kidneys. Most clinicians decided when to biopsy jointly with the Organ Procurement Organization (OPO) (82%) based on formal criteria for the decision (72%), although 41% reported having requested a biopsy outside of the criteria. Most respondents used a semiquantitative scoring system for interpretation (57%). Many respondents reported rarely or never having access to renal specialty pathologists (37%) or to telepathology (59%). Most respondents reported that a favorable biopsy result would encourage them to accept a "marginal" donor kidney (72%); nearly half (46%) indicated that an unfavorable biopsy result would lead to decline of a standard criteria kidney. CONCLUSION: Procurement biopsies are commonly used in organ acceptance decisions despite inconsistent access to experienced renal pathologists and heterogeneous approaches to criteria, scoring, and interpretation. Ongoing study and consensus building are needed to direct procurement biopsy practice toward increasing organ utilization and reducing allocation inefficiency.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Lentine KL, Fleetwood VA, Caliskan Y, et al. Deceased Donor Procurement Biopsy Practices, Interpretation, and Histology-Based Decision-Making: A Survey of US Kidney Transplant Centers. Kidney Int Rep. 2022. PMID: 35685316. doi:10.1016/j.ekir.2022.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。